RX:CA:TSV-Biosyent Inc. (CAD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 10.7

Change

-0.15 (-1.38)%

Market Cap

USD 0.12B

Volume

1.90K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis. In addition, the company provides Cathejell, a lubricant with anesthetic with the indication of lubricating and opening the urethra before the insertion of the catheter; Combogesic to manage mild to moderate acute pain and reduction of fever in adults; and Proktis-M, a rectal suppository for the healing of the anus and rectum. The company sells its products through wholesalers and retail pharmacy chains. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006. BioSyent Inc. was founded in 2006 and is headquartered in Mississauga, Canada.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-19 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZYUS:CA ZYUS Life Sciences Corporation

-0.03 (-3.16%)

USD 0.07B
SBBC:CA Simply Better Brands Corp

-0.01 (-1.64%)

USD 0.06B
LOVE:CA Cannara Biotech Inc

+0.02 (+3.08%)

USD 0.06B
LSL:CA LSL Pharma Group Inc.

+0.02 (+4.44%)

USD 0.05B
DB:CA Decibel Cannabis Company Inc

+0.01 (+7.14%)

USD 0.03B
ROMJ:CA Rubicon Organics Inc

-0.01 (-2.22%)

USD 0.03B
PCLO:CA Pharmacielo Ltd

N/A

USD 0.02B
MPH:CA Medicure Inc

N/A

USD 0.01B
DHB:CA Delivra Health Brands Inc.

-0.01 (-20.00%)

USD 7.82M
CANB:CA CanadaBis Capital Inc

N/A

USD 7.60M

ETFs Containing RX:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 16.05% 81% B- 66% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.05% 81% B- 66% D+
Trailing 12 Months  
Capital Gain 34.09% 92% A 75% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 34.09% 92% A 75% C
Trailing 5 Years  
Capital Gain 78.04% 100% F 75% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 78.04% 100% F 75% C
Average Annual (5 Year Horizon)  
Capital Gain 15.62% 88% B+ 65% D
Dividend Return 15.62% 88% B+ 65% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 25.79% 88% B+ 85% B
Risk Adjusted Return 60.55% 100% F 96% N/A
Market Capitalization 0.12B 100% F 94% A

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.